---
title: "Nomura Cuts CSPC PHARMA  TP to HKD10.31, Expects Mild Growth in 2Q Drug Sales"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/293876617.md"
description: "Nomura lowered its target price for CSPC PHARMAto HKD10.31 from HKD12.04, while maintaining a Buy rating. The broker expects mild Q2 drug sales growth and increased collaboration revenue. FY2026 revenue and earnings forecasts were cut by 7.6% and 17.4% respectively, due to reduced sales expectations and higher expenses. These forecasts remain below market consensus, primarily reflecting different assumptions on out-licensing revenue recognition from the AstraZeneca agreement."
datetime: "2026-07-27T03:47:04.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/293876617.md)
  - [en](https://longbridge.com/en/news/293876617.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/293876617.md)
generator: "portal-rs"
---

# Nomura Cuts CSPC PHARMA  TP to HKD10.31, Expects Mild Growth in 2Q Drug Sales

Nomura published a report expecting mild growth in drug sales and increased collaboration revenue for CSPC PHARMA (01093.HK) -0.140 (-1.637%) Short selling $378.15M; Ratio 32.246% in the second quarter. It estimated that second-quarter sales and profit would rise 10.3% YoY and 13.1% YoY, respectively. For 2H26, the broker estimated that CSPC PHARMA's revenue and net profit would increase 22% YoY and 157% YoY from the low base in 2H25 to RMB15.5 billion and RMB3.4 billion, respectively, mainly considering the recognition of about RMB3.2 billion in out-licensing revenue from the AstraZeneca (AZN) agreement. Finished drug sales in 2H26 are expected to grow steadily by 5% YoY, flat from 1H26. The broker maintained its Buy rating and lowered the TP from HKD12.04 to HKD10.31.

The broker lowered its FY2026 revenue and earnings forecasts by 7.6% and 17.4%, respectively, mainly due to reduced forecasts for drug and API sales, as well as higher R&D and selling expense forecasts. The forecasts are 8.9% and 29.4% below market consensus, respectively, possibly due to different assumptions regarding the amount of collaboration revenue recognition mentioned above. (ha/da)(HK stocks quote is delayed for at least 15 mins.Short Selling Data as at 2026-07-24 16:25.)

### Related Stocks

- [01093.HK](https://longbridge.com/en/quote/01093.HK.md)
- [8604.JP](https://longbridge.com/en/quote/8604.JP.md)
- [NMR.US](https://longbridge.com/en/quote/NMR.US.md)
- [AZN.US](https://longbridge.com/en/quote/AZN.US.md)
- [AZN.UK](https://longbridge.com/en/quote/AZN.UK.md)

## Related News & Research

- [CSPC Pharma wins China NMPA clearance to start Phase 1 trial of SYH2092 obesity drug](https://longbridge.com/en/news/297512143.md)
- [CSPC Pharma says FDA grants Fast Track status to SYS6090 for MSS/pMMR metastatic colorectal cancer](https://longbridge.com/en/news/297024431.md)
- [CSPC’s SYS6010 Wins Third Breakthrough Therapy Tag in High-Need Cancer Indications](https://longbridge.com/en/news/297638498.md)
- [1 Cheap Stock Under $10 for Aggressive Investors to Buy on the Dip](https://longbridge.com/en/news/297683938.md)
- [M Stanley Raises CSPC PHARMA  TP to HKD12, Rating Overweight](https://longbridge.com/en/news/296557755.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**